Peter Geschek
Long only

Acadia: The Best Hope For Parkinson's Psychosis Sufferers

One of the most distressing symptoms of Parkinson's disease is the psychosis which causes people to have hallucinations and delusions. It is a quite common condition which affects about 40 percent of all patients with Parkinson's disease. And the number of Parkinson's patients is growing rapidly along with the increase of the elderly population.

There is no FDA approved drug for Parkinson's psychosis.

Acadia Pharmaceuticals' (NASDAQ:ACAD) promising new drug, Pimavanserin is expected to be submitted for approval at the end of 2014 and possibly begin producing revenue from 2015.

Acadia, located in San Diego, California, is a small company with less than 50 employees.

Pimavanserin is special because it does not cause serious side effects like other...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details